Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

被引：0

作者：

Jeong Eun Kim

Joung-Soon Jang

Jae-Weon Kim

Yong Lee Sung

Chi-Heum Cho

Myung-Ah Lee

Do-Jin Kim

Myung-Ju Ahn

Kil Yeon Lee

Sun Jin Sym

Myong Choel Lim

Hun Jung

Eun Kim Cho

Kyung Wan Min

机构：

[1] Asan Medical Center,Department of Oncology

[2] University of Ulsan College of Medicine,Department of Internal Medicine

[3] Chung-Ang University College of Medicine,Department of Obstetrics and Gynecology

[4] Seoul National University College of Medicine,Division of Respiratory and Critical Care Medicine, Department of Internal Medicine

[5] Korea University College of Medicine,Department of Obstetrics and Gynecology, School of Medicine

[6] Keimyung University,Department of Medical Oncology

[7] Seoul St. Mary’s Hospital,Division of Allergy and Respiratory Medicine, Department of Internal Medicine

[8] The Catholic University of Korea,Division of Hematology

[9] Soonchunhyang University Bucheon Hospital,Oncology, Department of Medicine, The Samsung Medical Center

[10] Soonchunhyang University College of Medicine,Department of Surgery

[11] Sungkyunkwan University School of Medicine,Division of Hematology and Medical Oncology, Department of Internal Medicine

[12] Kyung Hee University School of Medicine,Gynecologic Cancer Branch, Research Institute and Hospital

[13] Gachon University Gil Medical Center,undefined

[14] Incheon Regional Cancer Center,undefined

[15] Gachon University School of Medicine,undefined

[16] National Cancer Center,undefined

[17] Merck Sharp & Dohme,undefined

来源：

Supportive Care in Cancer | 2017年 / 25卷

关键词：

Aprepitant; Neurokinin-1 receptor antagonists; Moderately emetogenic chemotherapy,; Chemotherapy-induced nausea and vomiting;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：801 / 809

页数：8

共 179 条

[1]

Coates A(1983)On the receiving end—patient perception of the side-effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 203-208

[2]

Abraham S(1996)On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 7 189-195

[3]

Kaye SB(1996)Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score Support Care Cancer 4 435-439

[4]

Sowerbutts T(2013)Emerging treatments in chemotherapy-induced nausea and vomiting Clin Adv Hematol Oncol 11 1-18

[5]

Frewin C(1988)The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy J Clin Oncol 6 1746-1752

[6]

Fox RM(2010)Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann Oncol 21 v232-v243

[7]

Tattersall MH(2005)Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822-2830

[8]

Griffin AM(2010)Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study Support Care Cancer 18 423-431

[9]

Butow PN(2003)Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 3090-3098

[10]

Coates AS(2003)The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the aprepitant protocol 052 study group J Clin Oncol 21 4112-4119

← 1 2 3 4 5 6 7 8 9 10 →